Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
Corbus Pharmaceuticals (CRBP) Stock Price & Analysis
2,115 Followers
CRBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.03 - $49.87
Previous Close$45.92
Volume3.92K
Average Volume (3M)289.84K
Market Cap
$488.60M
Enterprise Value$490.71M
Total Cash (Recent Filing)$20.91M
Total Debt (Recent Filing)$20.88M
Price to Earnings (P/E)-6.6
Beta0.97
Next Earnings
Aug 08, 2024EPS Estimate
-$1.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.97
Shares Outstanding10,686,693
10 Day Avg. Volume255,932
30 Day Avg. Volume289,838
Standard Deviation0.54
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-66.54
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-14.29
Forecast
1Y Price Target
$63.00Price Target Upside37.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Corbus Pharmaceuticals News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $3.03 and its highest was $49.87 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Currently, no data Available
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Aug 08, 2024 which is in 83 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on May 07, 2024. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.09 by $0.26.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -$1.38.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 10,686,693 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.09. Following the earnings report the stock price went up 2.447%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Among the largest hedge funds holding Corbus Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Corbus Pharmaceuticals’s shares valued at 2M.
---
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.00 (37.80% Upside)
$63.00 (37.80% Upside)
Blogger Sentiment
Bullish
CRBP Sentiment 85%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $23.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
340.05%
12-Months-Change
Fundamentals
Return on Equity
-59.52%
Trailing 12-Months
Asset Growth
143.48%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.
---
CRBP Stock 12 Month Forecast
Average Price Target
$63.00
▲(37.80% Upside)
Technical Analysis
Best Analysts Covering CRBP
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+105.70%
reiterated a buy rating 10 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +105.70% per trade.
---